✦ LIBER ✦

Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors

✍ Scribed by Sarah A. Taylor; John Crowley; F. Stephen Vogel; Jeannette J. Townsend; Harmon J. Eyre; Kurt A. Jaeckle; Harry E. Hynes; Jerry T. Guy

Publisher: Springer US
Year: 1991
Tongue: English
Weight: 147 KB
Volume: 9
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00175089

No coin nor oath required. For personal study only.

✦ Synopsis

Twenty-three patients with malignant central nervous system tumors were treated with fludarabine phosphate (2-FAMP) on a 5 day bolus schedule. One brief partial response was observed in 20 malignant astrocytoma patients. 2FAMP as given in this protocol is inactive in previously treated patients with recurrent malignant astrocytomas.

📜 SIMILAR VOLUMES

Phase II evaluation of topotecan for ped

Phase II evaluation of topotecan for pediatric central nervous system tumors

✍ Susan M. Blaney; Peter C. Phillips; Roger J. Packer; Richard L. Heideman; Stacey 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 473 KB 👁 2 views

## BACKGROUND. Topotecan is a topoisomerase I inhibitor that has good penetration across the blood-brain barrier and significant antitumor activity against human brain tumor xenografts. In a Phase I trial in children with refractory cancer, topotecan was well tolerated when administered as a 24-ho

Phase II study of homoharringtonine in p

Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors

✍ Lynn G. Feun; Niramol Savaraj; Howard Landy; Howard Levin; Theodore Lampidis 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 337 KB

Phase II evaluation of echinomycin (NSC-

Phase II evaluation of echinomycin (NSC-526417) in patients with central nervous system malignancies

✍ Sarah A. Taylor; John Crowley; Jennette Townsend; F. Stephen Vogel; Harmon Eyre; 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 298 KB

Immunological studies in patients with c

Immunological studies in patients with central nervous system tumors

✍ L. Palmas; Viviana Moschese; Elena Galli; Concetta Barbieri; V. R. M. Lombardi; 📂 Article 📅 1987 🏛 Springer US 🌐 English ⚖ 692 KB

Impairment of cell-mediated immunity in patients with primary central nervous system (CNS) tumors has repeatedly been reported but data to demonstrate the undelying immunological defect are not univocal. This report concerns a series of 31 patients harboring a glioma in which we studied: 1) peripher

A phase II evaluation of thiotepa in ped

A phase II evaluation of thiotepa in pediatric central nervous system malignancies

✍ Richard L. Heideman; Roger J. Packer; Gregory H. Reaman; Jeffrey C. Allen; Bever 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 489 KB 👁 2 views

Phase II trial of fludarabine phosphate

Phase II trial of fludarabine phosphate (F-Ara-AMP) in patients with advanced breast cancer

✍ A. Mittelman; R. Ashikari; T. Ahmed; S. Savona; P. Arnold; Z. Arlin 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 181 KB

Eighteen patients with advanced breast cancer were entered into a phase II study of fludarabine phosphate. Fludarabine phosphate was given by continuous infusion for 5 days, at a starting dose of 20 mg/m2 per day for patients previously treated with two or more regimens and 25 mg/m2 per day for mini